How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease (vol 12, pg 1, 2018)

被引：0
|
作者：
Naviglio, S.
Giuffrida, P.
Stocco, G.
机构：
来源：
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | 2018年 / 12卷 / 08期
关键词：
D O I：
10.1080/17474124.2018.1500981
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：I / I
页数：1
相关论文
共 50 条
  • [1] How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease
    Naviglio, Samuele
    Giuffrida, Paolo
    Stocco, Gabriele
    Lenti, Marco Vincenzo
    Ventura, Alessandro
    Corazza, Gino Roberto
    Di Sabatino, Antonio
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (08) : 797 - 810
  • [2] European guidelines for the use of anti-tumour necrosis factor agents in inflammatory bowel disease
    Kruis, W
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2001, 16 (01) : 12 - 13
  • [3] European guidelines for the use of anti-tumour necrosis factor agents in inflammatory bowel disease
    Wolfgang Kruis
    [J]. International Journal of Colorectal Disease, 2001, 16 : 12 - 13
  • [4] Therapeutic drug monitoring of anti-tumour necrosis factor-a agents in inflammatory bowel disease
    Mitrev, Nikola
    Leong, Rupert W.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 303 - 317
  • [5] Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
    Konstantinos Papamichael
    Severine Vermeire
    [J]. World Journal of Gastroenterology, 2015, (16) : 4773 - 4778
  • [6] Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
    Papamichael, Konstantinos
    Vermeire, Severine
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (16) : 4773 - 4778
  • [7] Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents
    Karmiris, Konstantinos
    Bossuyt, Peter
    Sorrentino, Dario
    Moreels, Tom
    Scarcelli, Antonella
    Legido, Jesus
    Dotan, Iris
    Naismith, Graham D.
    Jussila, Airi
    Preiss, Jan C.
    Kruis, Wolfgang
    Li, Andy C. Y.
    Bouguen, Guillaume
    Yanai, Henit
    Steinwurz, Flavio
    Katsanos, Konstantinos H.
    Subramaniam, Kavitha
    Tarabar, Dino
    Zaganas, Ioannis V.
    Ben-Horin, Shomron
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 (05): : 382 - 389
  • [8] A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease
    Thomas, Pepijn W. A.
    Chin, Paul K. L.
    Barclay, Murray L.
    [J]. INTERNAL MEDICINE JOURNAL, 2021, 51 (03) : 341 - 347
  • [9] Use of anti-tumour necrosis factor agents in inflammatory bowel disease - European guidelines for 2001-2003
    Schreiber, S
    Campieri, M
    Colombel, JF
    van Deventer, SJH
    Feagan, B
    Fedorak, R
    Forbes, A
    Gassull, M
    Gendre, JP
    van Hogezand, RA
    Lofberg, R
    Modigliani, R
    Pallone, F
    Petritsch, W
    Prantera, C
    Rampton, D
    Seibold, F
    Vatn, M
    Zeitz, M
    Rutgeerts, P
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2001, 16 (01) : 1 - 11
  • [10] Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements
    Maria Giraldez-Montero, Jose
    Gonzalez-Lopez, Jaime
    Campos-Toimil, Manuel
    Jesus Lamas-Diaz, Maria
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (05) : 2216 - 2227
12345